← Leaderboards
John Michael Routes
National Jewish Health
$4,411,984
Attributed
$4,668,469
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $692.6K · FY2005–14$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$4,668,469 · 6
By mechanism
R01$4,010,407 · 4
R56$378,260 · 1
R34$279,802 · 1
Top collaborators
- Fracisco A Bonilla1 shared
- Charlotte Cunningham-Rundles1 shared
- Raif Salim Geha1 shared
- Katherne E Gundling1 shared
- Michael E Kelly1 shared
- Laura L Koth1 shared
- Anna Kovalszki1 shared
- David J Rawlings1 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Ivana V Yang$13,155,768
- Diane Sullivan$3,882,412
- Eric T Clambey$1,805,865
- Talmadge E King$1,393,645
- Harold R Collard$36,121,069
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMalignant NeoplasmsNeoplastic CellNatural Killer CellsTumor AntigensCellular ImmunityClinical TrialsResponseT-LymphocyteBinding (Molecular Function)Mortality Vital StatisticsCellsMediatingHuman PapillomavirusDendritic CellsImmuneMonoclonal AntibodiesCd8b1 GeneClinical TreatmentCreb-Binding ProteinAdenovirusesHuman Papillomavirus 16BiopsyAbbreviations
Grant awards (17)
GLILD in CVID$279,802
R34 · FY2014 · AI · contact PI
Autoantibody production and regulatory T cells$378,260
R56 · FY2012 · AI · contact PI
Lymphoproliferative Disorders in Primary Immunodeficiencies$314,363
R01 · FY2012 · CA · contact PI
Lymphoproliferative Disorders in Primary Immunodeficiencies$282,926
R01 · FY2011 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$279,215
R01 · FY2011 · CA · contact PI
Lymphoproliferative Disorders in Primary Immunodeficiencies$314,363
R01 · FY2010 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$287,850
R01 · FY2010 · CA · contact PI
Lymphoproliferative Disorders in Primary Immunodeficiencies$314,363
R01 · FY2009 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$287,850
R01 · FY2009 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$22,010
R01 · FY2009 · CA · contact PI
Lymphoproliferative Disorders in Primary Immunodeficiencies$314,363
R01 · FY2008 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$287,850
R01 · FY2008 · CA · contact PI
Anti-tumorigenic Activity of Adenovirus E1A$287,850
R01 · FY2007 · CA · contact PI
AMID in Apoptosis and p53-Mediated Downstream Effects$279,702
R01 · FY2005 · CA
DISSIMILAR IMMUNOGENICITIES OF ELA AND E7 ONCOPROTEINS$253,204
R01 · FY2002 · CA
DISSIMILAR IMMUNOGENICITIES OF ELA AND E7 ONCOPROTEINS$245,831
R01 · FY2001 · CA
DISSIMILAR IMMUNOGENICITIES OF ELA AND E7 ONCOPROTEINS$238,667
R01 · FY2000 · CA